Menu
Search
|

Menu

Close
X

bluebird bio Inc BLUE.OQ (NASDAQ Stock Exchange Global Select Market)

106.63 USD
-0.23 (-0.22%)
As of 12:52 PM EDT
Previous Close 106.86
Open 107.00
Volume 39,000
3m Avg Volume 196,936
Today’s High 107.87
Today’s Low 105.03
52 Week High 163.33
52 Week Low 87.64
Shares Outstanding (mil) 55.12
Market Capitalization (mil) 7,541.96
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 22 analysts

KEY STATS

Revenue (mm, USD)
FY19
12
FY18
55
FY17
35
FY16
6
EPS (USD)
FY19
-2.992
FY18
-10.670
FY17
-9.930
FY16
-7.062
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
147.61
7.90
Price to Book (MRQ)
vs sector
4.25
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.64
LT Debt to Equity (MRQ)
vs sector
0.00
12.61
Return on Investment (TTM)
vs sector
-32.26
12.69
Return on Equity (TTM)
vs sector
-36.20
17.13

EXECUTIVE LEADERSHIP

Daniel Lynch
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Nick Leschly
President, Chief Executive Officer, Director, Since 2010
Salary: $560,000.00
Bonus: $431,200.00
William Baird
Chief Financial Officer, Since 2019
Salary: --
Bonus: --
Kory Wentworth
Principal Accounting Officer, Vice President - Finance, Since 2017
Salary: --
Bonus: --
Philip Gregory
Chief Scientific Officer, Since 2015
Salary: $405,000.00
Bonus: $212,300.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

60 Binney St
CAMBRIDGE   MA   02142-1512

Phone: +1339.4999300

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

SPONSORED STORIES